[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-333034-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-333034-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-lancet-commission-on-prostate-cancer-planning-for-the-surge-in-cases-commission-report","The Lancet Commission on prostate cancer: planning for the surge in cases - Commission report","","The document is a Lancet Commission author manuscript describing a coordinated, four–working-group effort to address major challenges in prostate cancer as case volumes rise. It details the Commission structure, leadership, and scope: strengthening evidence in low- and middle-income countries, reducing overdiagnosis while improving detection of curable clinically significant disease, improving treatment selection, and enhancing therapy for advanced prostate cancer. It also includes analysis and projection of population trends and author authorship and approval statements, alongside declarations of interests.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-lancet-commission-on-prostate-cancer-planning-for-the-surge-in-cases-commission-report/333034/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-lancet-commission-on-prostate-cancer-planning-for-the-surge-in-cases-commission-report/333034.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How is the Commission organized and what do the working groups focus on?","Question",{"text":63,"@type":64},"The Commission is split into four working groups, each with its own chair. Working Group 1 focuses on improving the evidence base in LMICs, Working Group 2 targets reducing overdiagnosis while increasing detection of curable clinically significant disease, Working Group 3 improves treatment selection, and Working Group 4 focuses on improved therapy for advanced prostate cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Who performed the analysis and projection of prostate cancer population trends?",{"text":68,"@type":64},"FB did the analysis and projection of prostate cancer population trends.",{"name":70,"@type":61,"acceptedAnswer":71},"What types of disclosures are included in the document?",{"text":72,"@type":64},"The document includes a Declaration of interests listing advisory roles, personal fees, stock options, patents, travel support, and other financial relationships for multiple contributors.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},333034,1790362082,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Europe PMC unders uthManuscripts Europe M eC und Author Manuscripts  \nEurope PMC Funders Group  \nAuthor Manuscript  \nLancet. Author manuscript; available in PMC 2025 February 04.  \nPublished in final edited form as:  \nLancet. 2024 April 27; 403(10437): 1683–1722. doi:10.1016/S0140-6736(24)00651-2 .  \nThis work is licensed under a BY 4.0 International license.  \nCorrespondence to: Nicholas D James.  \nCorrespondence to: Prof Nicholas D James, Institute of Cancer Research, London SW3 6JB, [UK nick.james@icr.ac.uk](UK nick.james@icr.ac.uk) .  \nContributors  \nThe Commission was chaired by NDJ. The Commission was split into four working groups, each with its own chair. Working Group 1, which focused on improving the evidence base in LMICs, was chaired by IT and also included SH, MS, BM, PV, AMo, MMor, JN’D, DH, VM, FB, HR, and EG. Working Group 2, which focused on reducing overdiagnosis while increasing detection of curable, clinically significant disease was chaired by JN’D and also included EC, AP, L-PX, RE, DT, OF, DM, CM, SL, BM, SH, ÁH, CP, and LM. Working Group 3, which focused on better treatment selection, was chaired by FF and also included BA-L, SL, MSH, JdB, PLN, GA, MJ, NT, AMo, MMor, AP, SH, SAA, BA-L, and BT. Working Group 4, which focused on improved therapy for advanced prostate cancer, was chaired by SG and also included JdB, MRS, NT, HS, DH, VM, IT, MSH, OF, SH, EG, and AMa. FB did the analysis and projection of prostate cancer population trends. NDJ drafted the Commission report, with assistance from IT, JN’D, FF, and SG. All authors reviewed and approved the final version.  \nDeclaration of interests  \nNDJ reports advisory board and personal fees from AstraZeneca, Bayer, Clovis, Janssen, Merck, Merck Sharp & Dohme, Novartis, Sanofi, Astellas, and AAA Accelerator Solutions. FF reports personal fees from Janssen, Astellas, Serimmune, Foundation Medicine, Exact Sciences, Bristol-Myers Squibb, Varian Medical Systems, Novartis, Roivant, Myovant, Bayer, BlueStar Genomics, Artera, Tempus, Genentech, PFS Genomics, and Amgen, and holds stock options in Serimmune, BlueStar Genomics, and Artera. SG reports fees from Tolremo, Ipsen, Silvio Grasso Consulting, WebMD–Medscape, the American Society of Clinical Oncology, European Society for Medical Oncology, Peer Voice, SAKK, the German-speaking European School of Oncology, Radiotelevisione Svizzera Italiana, the Swiss Academy of Multidisciplinary Oncology, Meister ConCept, AdMeTech Foundation, EPG Health, Intellisphere, and Schweizerische Gessellschaft für Medizineische Onkologie. SG also reports travel support from AstraZeneca, Bayer, Intellisphere, and Gilead, paid advisory board participation for Merck Sharp & Dohme, Telixpharma, Bristol-Myers Squibb, AAA International, Orion, Bayer, Novartis, Modra Pharmaceuticals, AstraZeneca, Myriad Genetic, Daiichi Sankyo, Boehringer Ingelheim, Innomedica, Macrogenics, and Pfizer, and holds a patent (WO2009138392) . BA-L reports fees from the Cancer Prevention and Research Institute of Texas, the Commonwealth Foundation, the Lyda Hill Foundation, Cancer Research UK, the Wellcome Trust, the Bob Champion Trust, AstraZeneca, Astex Pharmaceuticals, the New York Genome Center, and Existentia, travel support from Cancer Research UK, Astex, the STAT summit, the American Society of Hematology, and the American Association for Cancer Research, and participation in a Cancer Research UK data strategy board. GA reports fees from Janssen, Novartis, Astellas, the Institute of Cancer Research, Veracyte, Artera, Pfizer, AstraZeneca, Astellas, Novartis, Arvinas, Bayer, Sanofi, Propella, and Orion, holds a patent related to blood-based methylation markers (GB1915469.9), and has received equipment from Agilent. EC reports fees from Janssen. RE reports book royalties plus support and fees from the UK National Institute for Health and Care Research, AstraZeneca, Bayer, Ipsen, the Active Surveillance Movember Committee, the American Society of Clinical Oncolog","cbCaipIXZy64WiYL","https://ap.wps.com/l/cbCaipIXZy64WiYL","pdf",3075148,79,"English","# Contributors and Commission structure\n## Working Group 1\n## Working Group 2\n## Working Group 3\n## Working Group 4\n# Declaration of interests","[{\"question\":\"How is the Commission organized and what do the working groups focus on?\",\"answer\":\"The Commission is split into four working groups, each with its own chair. Working Group 1 focuses on improving the evidence base in LMICs, Working Group 2 targets reducing overdiagnosis while increasing detection of curable clinically significant disease, Working Group 3 improves treatment selection, and Working Group 4 focuses on improved therapy for advanced prostate cancer.\"},{\"question\":\"Who performed the analysis and projection of prostate cancer population trends?\",\"answer\":\"FB did the analysis and projection of prostate cancer population trends.\"},{\"question\":\"What types of disclosures are included in the document?\",\"answer\":\"The document includes a Declaration of interests listing advisory roles, personal fees, stock options, patents, travel support, and other financial relationships for multiple contributors.\"}]","The Lancet Commission on prostate cancer: planning for the surge in cases - Commission report | PDF",1790000402,199]